Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis

Lignende værker

• Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering—A Cross-Sectional Analysis
  af: Stockklausner, Clemens, et al.
  Udgivet: (2016)
• Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act
  af: Lutz, Thomas, et al.
  Udgivet: (2016)
• Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
  af: Ries, Markus, et al.
  Udgivet: (2015)
• Pressure for drug development in lysosomal storage disorders – a quantitative analysis thirty years beyond the US orphan drug act
  af: Mechler, Konstantin, et al.
  Udgivet: (2015)
• Ten Years after the International Committee of Medical Journal Editors' Clinical Trial Registration Initiative, One Quarter of Phase 3 Pediatric Epilepsy Clinical Trials Still Remain Unpublished: A Cross Sectional Analysis.
  af: Anette Lampert, et al.
  Udgivet: (2016-01-01)